| 17.63 0.16 (0.92%) | 04-24 15:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Ortho Clinical Diagnostics Holdings plc, established in 1939 and based in Raritan, New Jersey, operates as a global provider of in-vitro diagnostic solutions. The company caters to both clinical laboratories and the transfusion medicine community, offering a comprehensive range of automated instruments together with the assays, reagents, and consumables required to produce test results. Their product portfolio includes clinical chemistry and immunoassay systems designed to detect and track disease progression across various therapeutic conditions, notably featuring tests for COVID-19 antibodies and antigens. Additionally, Ortho Clinical Diagnostics provides immunohematology instruments and tests crucial for blood typing, ensuring patient-donor compatibility during transfusions, along with donor screening tools to identify infectious diseases in blood and plasma. Beyond diagnostic products, the company also engages in contract manufacturing and orthocare services. Its offerings are widely deployed in hospitals, laboratories, clinics, blood banks, and donor centers.
Fri, 04 Sep 2026
Ortho Clinical Diagnostics Holdings plc (OCDX) Peer Comparison – Compare with Others - Value Research
Wed, 24 Apr 2024
Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX) - www.intelligentinvestor.com.au
Sun, 27 Nov 2022
Stephen H. Wise Net Worth (2026) - GuruFocus
Sun, 02 Jan 2022
Quidel Corp. to Acquire Ortho Clinical Diagnostics - citybiz
Tue, 28 Dec 2021
Quidel Corporation Acquires Ortho Clinical Diagnostics for $6B - HIT Consultant
Thu, 23 Dec 2021
Quidel to buy Ortho Clinical for $6 bln to boost diagnostics portfolio - Reuters
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|